Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessShould You Invest in Cassava Technologies Inc (SAVA)?

Should You Invest in Cassava Technologies Inc (SAVA)?

Add to Favorite
Added to Favorite

 

Photo Credit Cassava Technologies

Cassava Sciences Inc (SAVA) has an InvestorsObserver grade of 61, putting it in the middle of the Biotechnology sector. A score of 61 indicates that Cassava Sciences Inc is more attractive than 61% of similar stocks in its sector.

Even though there are currently 6 million instances of Alzheimer’s disease in the United States alone, and that number is projected to increase to 13 million by 2050, it is still unknown to scientists how the disease manifests to cause the symptoms that it does.

According to current theories, certain variations of the protein beta-amyloid cluster together in the brain’s spaces between neurons, impairing memory and causing Alzheimer’s disease symptoms.

Overall, analysts gave Cassava Sciences Inc a grade of 53, placing it in the top 53% of all rated companies. As an industry, biotechnology ranks 46th out of a total of 148.

There was no debt and $201 million in liquid assets as of December 31st, 2022, down from $233.4 million in the prior year. The November 2022 sale of 1.7 million shares of common stock generated net proceeds of $47.3 million, which was reflected in the company’s cash balance at year’s close.

Our Alzheimer’s disease clinical initiative is the primary driver of our projected $45 million to $50 million net cash used for operations in the first half of 2023.

How Groupon Will Revolutionize And Help The Retail Industry Post Covid -19

Subscribe to get Latest News Updates

Latest News

You may like more
more

Walmart introduces virtual and AI-powered shopping for web fans, CWEB reports

Walmart (WMT), the leading retailer in North America, has...

Wayfair Inc. (NYSE:W) Q3 2024 Earnings Report Highlights

Wayfair reported an earnings per share (EPS) of -$0.60,...

LyondellBasell Industries N.V. (NYSE:LYB) Faces Financial Challenges Despite Strong Market Presence

LyondellBasell Industries N.V. (NYSE:LYB) reported earnings per share (EPS)...

Brunswick Corporation (NYSE: BC) Faces Market Challenges Despite Strong Product Range

Brunswick Corporation (NYSE:BC) reported third-quarter earnings per share (EPS)...